PHVS
Pharvaris N.V.
NASDAQ · Healthcare · Biotechnology · NL
$35.25
−1.15%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 106.4K | — | — | — | — |
| Gross Profit | (106.4K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 129.6M | 124.5M | 98.6M | 65.6M | 57.4M |
| SG&A Expense | 53.3M | 45.3M | 47.1M | 31.3M | 29.3M |
| General & Admin Expense | 39.1M | 45.3M | 46.7M | 31.3M | 29.0M |
| Selling & Marketing Expense | — | — | 400.0K | — | 300.0K |
| Other Expenses | — | — | 0.00 | — | 0.00 |
| Total Operating Expenses | 182.9M | 169.8M | 145.7M | 96.9M | 86.7M |
| Cost and Expenses | 183.1M | 169.8M | 145.7M | 96.9M | 86.7M |
| Operating Income (EBIT) | (183.1M) | (169.8M) | (145.7M) | (96.9M) | (86.7M) |
| Non-Operating | |||||
| Interest Income | 5.8M | — | 5.5M | — | 16.11 |
| Interest Expense | 87.8K | — | — | — | 16.1K |
| Net Interest Income | 5.7M | — | 5.5M | — | (16.1K) |
| Other Non-Op Income/Expense | 13.8M | (3.9M) | 13.3M | (2.9M) | 11.1M |
| Non-Operating Income (excl Interest) | (10.4M) | 3.9M | (167.00) | 2.9M | (0.00) |
| EBT (Pre-Tax Income) | (169.2M) | (173.7M) | (132.4M) | (99.8M) | (75.7M) |
| Income Tax Expense | 2.4M | 2.0M | 1.8M | 1.0M | 679.1K |
| Bottom Line | |||||
| Net Income | (171.6M) | (175.7M) | (134.2M) | (100.9M) | (76.3M) |
| Earnings from Cont. Ops | (171.6M) | (175.7M) | (134.2M) | (100.9M) | (76.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (171.6M) | (175.7M) | (134.2M) | (100.9M) | (76.3M) |
| Per Share | |||||
| Basic EPS | ($2.70) | ($2.97) | ($2.48) | ($2.63) | ($2.27) |
| Diluted EPS | ($2.70) | ($2.97) | ($2.48) | ($2.63) | ($2.27) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 68.1M | 59.2M | 54.0M | 38.4M | 33.6M |
| Diluted Shares Outstanding | 68.1M | 59.2M | 54.0M | 38.4M | 33.6M |
| Profitability Metrics | |||||
| EBITDA | (172.2M) | (173.3M) | (145.6M) | (99.6M) | (86.6M) |
| D&A | 442.0K | 418.4K | 95.0K | 257.6K | 152.9K |
| EBIT | (172.7M) | (173.7M) | (145.7M) | (99.8M) | (86.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026